CCRIs 6181 en es it fr

CCRIs 6181 Brand names, CCRIs 6181 Analogs

CCRIs 6181 Brand Names Mixture

  • No information avaliable

CCRIs 6181 Chemical_Formula

C4H7N1O4

CCRIs 6181 RX_link

No information avaliable

CCRIs 6181 fda sheet

CCRIs 6181 msds (material safety sheet)

http://domino.solutia.com/solutia/smsdslib.nsf/0/561ad1a8b4bae67c8625636000511152/$FILE/English.pdf

CCRIs 6181 Synthesis Reference

No information avaliable

CCRIs 6181 Molecular Weight

133.104 g/mol

CCRIs 6181 Melting Point

230 oC

CCRIs 6181 H2O Solubility

4.5 g/l

CCRIs 6181 State

Solid

CCRIs 6181 LogP

-0.67 +/- 0.36

CCRIs 6181 Dosage Forms

Capsules and powder

CCRIs 6181 Indication

There is no support for the claim that aspartates are exercise performance enhancers, i.e. ergogenic aids.

CCRIs 6181 Pharmacology

L-aspartate is considered a non-essential amino acid, meaning that, under normal physiological conditions, sufficient amounts of the amino acid are synthesized in the body to meet the body's requirements. L-aspartate is formed by the transamination of the Krebs cycle intermediate oxaloacetate. The amino acid serves as a precursor for synthesis of proteins, oligopeptides, purines, pyrimidines, nucleic acids and L-arginine. L-aspartate is a glycogenic amino acid, and it can also promote energy production via its metabolism in the Krebs cycle. These latter activities were the rationale for the claim that supplemental aspartate has an anti-fatigue effect on skeletal muscle, a claim that was never confirmed.

CCRIs 6181 Absorption

Absorbed from the small intestine by an active transport process

CCRIs 6181 side effects and Toxicity

Mild gastrointestinal side effects including diarrhea. LD50 (rat) > 5,000 mg/kg.

CCRIs 6181 Patient Information

No information avaliable

CCRIs 6181 Organisms Affected

Humans and other mammals